Blenrep demonstrates improved overall survival in the DREAMM-7 phase III trial for relapsed/refractory multiple myeloma.

Antisense oligonucleotide (ASO) drugs represent a significant branch of the small nucleic acid therapeutic field, functioning as molecules that regulate gene expression through specific binding to mRNA.

Levicept Unveils Promising Phase II Results for LEVI-04, a New Neurotrophin-3 Inhibitor, in Treating Moderate to Severe Osteoarthritis at ACR Convergence 2024.

Suzetrigine is a small molecule drug developed by Vertex Pharmaceuticals, Inc. It is designed to target the Nav1.8 channel.

Sandoz has obtained approval from the European Commission for Afqlir® (aflibercept), enhancing its prominent biosimilar lineup.

Infliximab is a chimeric monoclonal antibody that targets tumor necrosis factor-alpha (TNF-α). Developed by Centocor.

This opinion endorses the approval of the amyloid-beta (Aβ) monoclonal antibody lecanemab for adult patients diagnosed with mild cognitive impairment and mild dementia due to Alzheimer's disease.

The small molecule drug, TYRA-300, developed by Tyra Biosciences, Inc., targets FGFR3 and falls under the category of rare pediatric disease.

Spirovant Sciences has administered the first dose to a patient in the SAAVe Phase 1/2 trial for its experimental aerosol-based genetic treatment for cystic fibrosis.

Enfortumab Vedotin-ejfv, also known as Padcev, is an antibody-drug conjugate (ADC) developed by Astellas Pharma and Seattle Genetics.

Kyverna Therapeutics Reveals Patient Data Showcasing KYV-101's Promise for Lupus Nephritis Treatment at ACR Convergence 2024 Symposium.

Pirtobrutinib is a small molecule drug developed by Redx Pharma Plc, targeting BTK C481S. Pirtobrutinib has received its first approval in the United States.